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LETTER TO THE EDITOR
Response to ‘Monitoring for post-transplant hepatocellular
carcinoma recurrence’
Sir,
We appreciate the response from Ortiz et al. regarding recom-
mendations for monitoring post-liver transplant (post-LTx)
patients for recurrent hepatocellular carcinoma (HCC). The
authors question the validity of our assertion that we have iden-
tified a group of patients at low risk for recurrent HCC after LTx
and that these patients can be monitored using a less stringent
surveillance strategy. Our report1 noted 13 recurrences in a popu-
lation of 122 patients undergoing LTx for HCC. None of the 68
patients whose explants were shown by pathological staging to be
within the Milan criteria experienced tumour recurrence. Our
more recent experience includes an additional four patients with
recurrence of HCC after LTx, in three of whom explants were
staged as beyond the Milan criteria. The explant from the fourth
patient was within the Milan criteria, but disease recurred 52
months after LTx. If we were to have applied an algorithm of
scanning every 3 months for 1 year and every 6 months for a
subsequent 2 years in the 69 patients whose explants were found
to be within the Milan criteria, 552 scans (eight scans per patient)
would have been performed over a 3-year period, but this protocol
would still have missed the recurrence at 52 months.
There are several important factors to consider in our study.1
Firstly, we used a cumulative staging process that included all
viable and non-viable tumours in the explant. Secondly, waitlist
time to transplant in our region is lengthy and many patients
require multiple bridging treatments in order to maintain eligi-
bility to remain on the list. This long wait time may itself separate
patients into low- and high-risk groups based on the number of
treatments required to maintain eligibility for transplant, and this
is reflected in cumulative staging. For example, patients with
favourable tumour biology who require only a single bridging
treatment over a wait time of 12–15 months are often found to
have completely necrotic nodules on explant and thus demon-
strate disease that would be considered to fall within the Milan
criteria, whereas patients who require two or more treatments
often have residual viable tumour andmay have vascular invasion,
which puts them in a higher risk category based on explant.
We maintain our assertion that patients with explant pathology
within the Milan criteria are at very low risk for recurrent HCC
after transplantation and therefore can be considered for less
stringent imaging surveillance. We would agree, however, that
other factors may have similar utility in stratifying patients into
high- and low-risk groups, such as the alpha-fetoprotein (AFP)
trajectory before transplant and the presence of vascular invasion.
Indeed, our results1 demonstrated that vascular invasion and the
presence of bilobar tumours were risk factors for recurrence.
A very important component of any surveillance strategy is the
premise that the timely detection of recurrence will lead to inter-
ventions that positively affect outcome. We and others have
adopted an aggressive approach to recurrent HCC after LTx with
the selective use of mTOR inhibitor-based immunosuppression,
liberal use of sorafenib and frequent use of loco-regional modali-
ties for solid organ recurrence. As such, we advocate aggressive
screening for patients who are at medium to high risk of recur-
rence, such as those with disease outside the University of Cali-
fornia San Francisco (UCSF) criteria with vascular invasion. By
contrast with this group, in the low-risk group identified in our
study,1 the yield of aggressive surveillance is quite low. Neverthe-
less, there remains little consensus on this matter and in fact the
HCC Clinical Practice Guidelines cited by Dr Ortiz et al. state that
after LTx for HCC, imaging should be performed only ‘as needed’.2
Defining this low-risk group and establishing a cost-effective and
patient-friendly surveillance regimen represent ongoing chal-
lenges within the transplant community and continued dialogue
is needed.
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